CREEK & RIVER (4763) Q2 2026 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2026 earnings summary
20 Jul, 2026Executive summary
Achieved record-high interim sales of ¥28,092 million, up 8.7% year-over-year, and interim net income of ¥2,214 million, up 50.7% year-over-year, with double-digit growth in operating and ordinary profit excluding the Takahashi Shoten Group impact.
Game and medical services segments rebounded after previous quarter struggles.
Takahashi Shoten Group consolidation led to a temporary operating loss but boosted interim net income due to tax effects.
Comprehensive income increased 45.3% year-over-year to ¥2,230 million.
Financial highlights
Sales: ¥28,092 million, up 8.7% year-over-year; operating profit: ¥2,138 million, down 2.6% year-over-year; ordinary profit: ¥2,112 million, down 6.8% year-over-year.
Interim net income: ¥2,214 million, up 50.7% year-over-year, aided by lower tax expenses.
Gross profit margin: 37.3% (down 0.6pt YoY); operating profit margin: 7.6% (down 0.9pt YoY).
Basic earnings per share for the six months: ¥104.72, up from ¥68.22 YoY; diluted EPS: ¥104.49.
Total assets as of August 31, 2025: ¥47,856 million; net assets: ¥17,426 million.
Outlook and guidance
Full-year forecast for FY2026: net sales of ¥60,000 million (+19.3% YoY), operating profit of ¥5,000 million (+38.3%), ordinary profit of ¥5,000 million (+35.3%), and profit attributable to owners of parent of ¥3,200 million (+42.1%).
Basic earnings per share for the full year projected at ¥149.88.
Annual dividend forecast for FY2026 is ¥45.00 per share, payout ratio 30%.
No change to full-year forecast despite interim net income exceeding plan due to expected higher tax expenses in H2.
Plans to increase sales in all categories, targeting double-digit profit growth.
Latest events from CREEK & RIVER
- Sales up 1% but operating profit down 20.2% YoY; strong full-year recovery forecast.4763
Q1 202420 Jul 2026 - Sales up 2.3% but operating profit down 15.6%; AI/DX and overseas growth prioritized.4763
Q2 202420 Jul 2026 - Sales up 1% YoY, profits down double digits, dividend cut, treasury buyback and new initiatives.4763
Q3 202520 Jul 2026 - Record sales and lower profits in FY2025; strong growth and higher dividends forecast for FY2026.4763
Q4 202520 Jul 2026 - Record sales and profit growth, with acquisitions fueling further expansion.4763
Q1 202620 Jul 2026 - Record sales and profit growth fueled by new segments, M&A, and strong business performance.4763
Q3 202620 Jul 2026 - Record sales and double-digit profit growth, with sales growth forecast to continue.4763
Q4 202620 Jul 2026 - Record Q1 sales and profits, driven by creative, medical, and incubation growth.4763
Q1 202720 Jul 2026